AFFILIATIONS
1 Affiliation Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University Chengdu, China, Sichuan, Chengdu, China
2 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
3 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
4 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
5 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
6 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
7 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
8 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
9 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
10 The Third People's Hospital of ChengDu, ChengDu, China
11 Capital Medical University Affiliated Beijing Anzhen Hospital Nanchong Hospital, Nanchong, China
12 Guangyuan Central Hospital, Guangyuan, China
13 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
14 Southwest Medical University Affiliated Hospital, Luzhou, China
15 Zigong First people's Hospital, Zigong, China
16 Department of Hematology,Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
ABSTRACT
Background:
Non-transfusion-dependent β-thalassemia (NTDT) is characterized by ineffective erythropoiesis and chronic anemia, resulting in substantial morbidity. Luspatercept promotes late-stage erythroid maturation through modulation of transforming growth factor-β (TGF-β) superfamily signaling and has demonstrated efficacy in NTDT. However, real-world evidence in Chinese patients remains limited.The genetic landscape of β-thalassemia differs substantially across geographic regions, with the β° CD17 mutation representing one of the most prevalent HBB variants in southern China. Whether genotype influences response to luspatercept remains unknown. This prospective, multicenter real-world cohort study—the first of its kind enrolling Chinese adults with NTDT—assessed the efficacy and safety of luspatercept, and investigated correlations between patient genotypes and hemoglobin treatment responses.
Methods:
This prospective multicenter real-world study enrolled adults with β-thalassemia or HbE/β-thalassemia and baseline hemoglobin (Hb) ≤100 g/L who received luspatercept in routine clinical practice. The primary endpoint was Hb increase ≥10 g/L from baseline during weeks 13–24. Secondary endpoints included response durability, transfusion burden, patient-reported outcome. Prespecified exploratory analyses identified clinical and genetic determinants of therapeutic response.
Results:
A total of 83 patients were enrolled. Baseline characteristics comprised a median age of 43.0 years (IQR 30.0–63.2), female sex accounting for 57.3% of participants, median body weight of 53.0 kg, and median Hb concentration of 72.0 g/L (IQR 61.0–82.0). The median fatigue score was 16.0 (IQR, 12.0–19.8). Nine patients (10.8%) had a prior transfusion history, and 27 (32.5%) carried the CD17 M/N genotype.
Primary endpoint: Among the 53 evaluable patients, 42 met the primary endpoint, corresponding to an Hb response rate of 79.2% (95% CI, 65.9-89.2). The median maximum rise in hemoglobin (Hb) was 21.0 g/L (IQR, 12.0–29.0), with 5 patients (9.4%) demonstrating Hb elevations greater than 40 g/L. Among the 30 patients with a follow-up duration of fewer than 13 weeks, the median Hb increment was 20.0 g/L (IQR, 6.2–29.8), and 63.3% of these patients attained an Hb rise of at least 10 g/L.
Secondary endpoints: Transfusion rates fell from 10.8% (9/83) in the 24 weeks prior to therapy to 3.6% (3/83) at Weeks 13–24. Among the 56 patients with paired assessments, fatigue scores improved significantly (median change, −4.0; IQR, −6.1 to −3.0; P < 0.001). Between Weeks 24 and 48, 39 of 46 evaluable patients (84.8%) preserved Hb elevations ≥10 g/L, five of whom attained Hb ≥115 g/L. Six out of 11 initial non-responders became responders following prolonged treatment.
Exploratory subgroup analyses: No significant associations were observed between Hb response and baseline Hb level, splenic status, ferritin level, prior transfusion history, body weight, or treatment duration (all P>0.05). In contrast, the CD17 M/N genotype was associated with a significantly lower response rate than other genotypes (60.0% vs 89.2%; OR, 0.20; 95% CI, 0.05–0.82; P=0.026), and this association remained significant after multivariable adjustment.
Safety: Luspatercept was generally well tolerated. The most common adverse events were limb or joint pain/swelling (n=4, 4.8%), hypertension (n=3, 3.6%), and bone pain (n=2, 2.4%). No serious adverse events, grade ≥3 treatment-emergent adverse events (TEAEs), or thromboembolic events were observed. Treatment discontinuation occurred in 18 patients (21.4%) and was not related to treatment toxicity.
Conclusions:
This first prospective multicenter real-world study of luspatercept in Chinese adults with NTDT demonstrated substantial and durable efficacy despite baseline anemia. Hb responses
were comparable to those reported in the BEYOND trial and were maintained through 48 weeks, accompanied by significant improvement in patient-reported fatigue and a favorable safety profile. Notably, the CD17 M/N genotype—one of the most prevalent HBB mutations in southern China—was independently linked to blunted therapeutic response, indicating its utility as a predictive biomarker for luspatercept efficacy. These findings provide important real-world evidence supporting individualized treatment strategies for Chinese patients with NTDT.
Keywords:NTDT β-thalassemia; luspatercept; ineffective erythropoiesis; hemoglobin response; real-world study
DISCLOSURES
He Li Sr: No relevant conflicts of interest to declare.